Japan Approves AstraZeneca Asthma Drug, To Be Marketed With Astellas
This article was originally published in PharmAsia News
Executive Summary
Japan's drug regulator approved U.K.-based AstraZeneca's Symbicort (budesonide) for treating adult asthma